+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Intranasal Drug Delivery - Global Market Trajectory & Analytics

  • ID: 516888
  • Report
  • February 2022
  • Region: Global
  • 459 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera

Global Intranasal Drug Delivery Market to Reach $71.3 Billion by 2026


As a direct result of technological advancements and increasing awareness among physicians and patients, a number of drug delivery options, including implantable, injectable, ocular, nasal, pulmonary, topical, transdermal, and transmucosal, are available to patients and care providers. The mode of delivering drugs to the target area of the patient body plays a decisive role in the effectiveness of the therapy. Pulmonary and nasal are the most popular approaches for drug delivery, owing to the ease of administration, particularly for patients requiring long-term therapy, improvement in quality of life of patients, the improved efficacy and bioavailability of administered drugs, lower risk of drug overdose, and easier compliance with stringent pharmaceutical regulations.

Nasal drug delivery route is suitable for systematic drug delivery, needleless vaccination, and for drug candidates with low oral absorption or vulnerable to first-pass effect in the human body. Intranasal drug delivery is a method involving the administration of drugs through the nasal cavity to produce a systemic or local therapeutic activity, with the exceptional vascular structure of the human nose making it suitable for administering small molecule drugs and biologics, and highly effective for treating local infections, and acute and chronic allergies. A plethora of local anesthetics, antibiotics, antihistamines, bronchodilators, calcium, corticosteroids, decongestant sprays, pain relief drugs, snuffs, supplements, vasoconstrictors and other drugs are administered through the intranasal route for chronic and acute treatments. Intranasal drugs are primarily administered in the form of ointments, sprays, powders, gels, and drops for treating allergic infections, analgesics, osteoporosis, vaccinations, pain management, anxiety, depression, and sexual dysfunction, among others.

Amid the COVID-19 crisis, the global market for Intranasal Drug Delivery estimated at US$49.5 Billion in the year 2020, is projected to reach a revised size of US$71.3 Billion by 2026, growing at a CAGR of 6.2% over the analysis period. Liquid Delivery Devices, one of the segments analyzed in the report, is projected to grow at a 5.8% CAGR to reach US$31.3 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Powder Delivery Devices segment is readjusted to a revised 7% CAGR for the next 7-year period. This segment currently accounts for a 31.5% share of the global Intranasal Drug Delivery market.



The U.S. Market is Estimated at $21.9 Billion in 2021, While China is Forecast to Reach $5.7 Billion by 2026


The Intranasal Drug Delivery market in the U.S. is estimated at US$21.9 Billion in the year 2021. The country currently accounts for a 42.05% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$5.7 Billion in the year 2026 trailing a CAGR of 8.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR while Rest of European market (as defined in the study) will reach US$6.1 Billion by the close of the analysis period.

North America represents the leading global market for intranasal drug delivery, driven by the growing prevalence of respiratory disorders, such as asthma and COPD; the high adoption of drug delivery technique in healthcare institutions; and the growing affinity of patients for affordable generic drugs. Technological developments are among the major factors driving the growth of the US drug delivery industry. The US drug delivery market has recorded significant developments in the past few years, and the search for new technologies represent a perennial effort aimed at achieving incremental benefits. In addition to scientific advancements, other factors and issues such as availability of financial support, changing scientific policies, therapeutic protocols, government regulations, and market forces have a bearing on the drug delivery market.

Europe represents the second largest market for intranasal drug delivery, trailed by the Asia-Pacific. The European market is expected to showcase fast growth fueled by the rising prevalence of chronic illnesses targeted for intranasal therapeutics, the growing markets for geriatric care, pediatric care, and home healthcare. Emerging countries in Asia, the Middle East and Latin America, are expected to spearhead the growth of the global intranasal drug delivery market by virtue of the large pool of target patients, relatively stronger GDP growth, improving public and private healthcare infrastructure, increasing healthcare spending, and increasing penetration of medical insurance. The Asia-Pacific, led by countries such as India and China, is expected to exhibit strong growth through the burgeoning population, rising per capita incomes, increasing patient awareness about the benefits of intranasal drugs, and increasing investment from drug companies.

Pressurized Metered Dose Inhalers Segment to Reach $12 Billion by 2026


In the global Pressurized Metered Dose Inhalers segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$7 Billion in the year 2020 will reach a projected size of US$10.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$837.6 Million by the year 2026, while Latin America will expand at a 7.5% CAGR through the analysis period.

Select Competitors (Total 77 Featured) -

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • Becton Dickinson and Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera
  • Novartis AG
  • OptiNose US Inc.
  • Pfizer, Inc.
Frequently Asked Questions about the Global Market for Intranasal Drug Delivery

What is the estimated value of the Global Market for Intranasal Drug Delivery?

The Global Market for Intranasal Drug Delivery was estimated to be valued at $49.5 Billion in 2020.

What is the growth rate of the Global Market for Intranasal Drug Delivery?

The growth rate of the Global Market for Intranasal Drug Delivery is 6.3%, with an estimated value of $71.3 Billion by 2026.

What is the forecasted size of the Global Market for Intranasal Drug Delivery?

The Global Market for Intranasal Drug Delivery is estimated to be worth $71.3 Billion by 2026.

Who are the key companies in the Global Market for Intranasal Drug Delivery?

Key companies in the Global Market for Intranasal Drug Delivery include AptarGroup, Inc., AstraZeneca Plc., Becton Dickinson and Company, GlaxoSmithKline Plc., Johnson & Johnson Inc., Merck & Co., Inc., Nemera, Novartis AG and Pfizer, Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Impact of Covid-19 and a Looming Global Recession
  • 2020: A Year of Disruption & Transformation
  • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021?
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • Promising Intranasal Vaccines to Nip COVID-19 Virus at Point of Entry
  • Rapid Progress despite Roadblocks
  • Nasal Sprays for Protection against COVID-19 Infection
  • Influencer Market Insights
  • World Market Trajectories
  • Intranasal Drug Delivery - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Intranasal Drug Delivery: A Prelude
  • Leading Indications and APIs Amenable to Nasal Drug Delivery
  • Regional Market Analysis
  • Why Nasal Application is Garnering Notable Attention for Drug Delivery
  • Limitations of Intranasal Drug Delivery
  • Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
  • Drug Delivery Pathways Related to the Nasal Cavity
  • Systemic delivery and Local Delivery Routes
  • Differences between Systemic Delivery and Local Effects
  • Challenges Involved In Formulating Nasal Drugs
  • Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
  • Nose-to-Brain Drug Delivery: An Evolving Area of Interest
  • Factors Inhibiting Nose-to-Brain Transportation of Drugs
  • Bioavailability: An Important Facet of Intranasal Drug Delivery
  • Traditional Vs. Advanced Intranasal Drug Formulation Types
  • Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application
  • Select FDA-Approved Nasal Products Compound (Trade Name) Indication Dosage Form Year
  • Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Rise in Prevalence of COPD Drives Opportunities
  • Global Prevalence of COPD: Percentage of Men and Women Affected by Age Group
  • Pharmaceutical and Medical Device Companies Vie to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
  • Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries
  • The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
  • The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
  • Intranasal Corticosteroids : A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
  • Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
  • Manufacturers Focus on Improved Nasal Delivery Platforms
  • Controlled Release Technology is the Buzz Word
  • Research on Nanocarrier-Based Intranasal Drug Delivery Systems Picks Up Pace
  • Potential Role in Treatment and Management of Coronavirus Infection
  • Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
  • Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
  • Top Nasal Inhalers, Sprays, and Drops Brands in the US (2019): Percentage Share Breakdown of Dollar Sales
  • Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
  • Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
  • Intranasal Therapeutics Delivery: A High Potential Method for Treating CNS Diseases
  • Researchers Develop Nasal Spray Treatment for Parkinson’s Disease
  • Future Opportunities in CNS Space
  • Intranasal Delivery of Stem Cells: A Primary Strategy for Treatment of CNS Disorders
  • Intranasal Delivery of Stem Cells: Limitations
  • Diagnosed Prevalence Cases of Parkinson’s Disease Across Select Countries
  • Intranasal Delivery of Peptide-Based Pharmaceuticals
  • Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
  • Select List of Nasal Biologics Available in the Market
  • Benefits of Bi-Directional Nasal Drug Delivery
  • Rise in Interest in Preservative-free Nasal Spray Formulations
  • Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Appendix: List of Select Intranasal Drugs in Phase III Clinical Trials
  • List of Select Intranasal Drugs for Pain Management in Phase III Clinical Trials
  • Select Intranasal Drugs for Cancer in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes in Phase III Clinical Trials
  • Select Intranasal Drugs for Nasal Polyps in Phase III Clinical Trials
  • Select Intranasal Drugs for Depression in Phase III Clinical Trials
  • Select Intranasal Drugs for Chronic Sinusitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Migraine in Phase III Clinical Trials
  • Intranasal Drugs for Allergic Rhinitis in Phase III Clinical Trials
  • Select Intranasal Drugs for Diabetes Mellitus in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials
  • Select Intranasal Drugs for Covid-19 in Phase III Clinical Trials

4. GLOBAL MARKET PERSPECTIVE


III. MARKET ANALYSIS

UNITED STATES

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)

CANADA

JAPAN

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)

CHINA

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)

EUROPE

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)

FRANCE

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)

GERMANY

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)

ITALY

UNITED KINGDOM

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)

SPAIN


RUSSIA


REST OF EUROPE

ASIA-PACIFIC

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)

AUSTRALIA

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)

INDIA

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)

SOUTH KOREA


REST OF ASIA-PACIFIC

LATIN AMERICA

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)

ARGENTINA


BRAZIL


MEXICO


REST OF LATIN AMERICA

MIDDLE EAST

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)

IRAN


ISRAEL


SAUDI ARABIA


UNITED ARAB EMIRATES


REST OF MIDDLE EAST

AFRICA

  • Intranasal Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)

IV. COMPETITION

  • Total Companies Profiled: 77
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AptarGroup, Inc.
  • AstraZeneca Plc.
  • Becton Dickinson and Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Inc.
  • Merck & Co., Inc.
  • Nemera
  • Novartis AG
  • OptiNose US Inc.
  • Pfizer, Inc.
Note: Product cover images may vary from those shown